ESRR'24

April 18-21, 2024 – Coimbra, Portugal

21st European Symposium on
Radiopharmacy &
Radiopharmaceuticals

FINAL PROGRAMMME

YOUR PARTNER FOR RADIOPHARAMCEUTICAL PRODUCTION

We bring ideas to life - for a better health worldwide.

ABX advanced biochemical compounds is a global frontrunner in radiopharmaceuticals, with focus on positron emission tomography (PET) tracers. We develop and produce compounds and components for any kind of radiotracer – from PET and SPECT precursors, PET reagent kits and cassettes, to complete radiopharmaceutical drug production in GMP environment.

ABX is a global success story: As market leader for radiopharmaceutical consumables we developed over the last years the ^{177}Lu-PSMA-617 – until phase II (then sublicensed to Endocyte, now Novartis) as well as ^{18}F-PSMA-1007 – now approved in several countries in Europe.

Our expertise

ABX

visit our website

WELCOME ADDRESS

Dear Colleagues and Friends,

It is our pleasure to welcome you to Coimbra to attend the 21st European Symposium on Radiopharmacy and Radiopharmaceuticals! Coimbra is a charming city in the center of Portugal. It was the first capital of the country from 1131 and our first kings ruled from here for over a century. The University of Coimbra, founded in 1290, is the oldest Portuguese speaking University and is classified as an UNESCO World Heritage site. Coimbra is embraced by the Mondego River and has lavish gardens, such as the iconic Botanical Garden or the romantic Quinta das Lágrimas, where the immortal love story of Pedro and Inês took place; imposing monuments and churches; fascinating museums and historical places. The congress venue, Convento de São Francisco, was founded in the beginning of the 16th century and throughout its long history served as a convent, a hospital and a military headquarter. It was recently renovated and nowadays it is a pivotal cultural and congress venue for the center of Portugal.

The Institute for Nuclear Sciences Applied to Health (ICNAS) is proud to host the 21st European Symposium on Radiopharmacy and Radiopharmaceuticals. ICNAS is a Research Institute of the University of Coimbra, dedicated to Medical Imaging and Translational Research. The Institute is a multimodal and multidisciplinary unit involving more than a hundred collaborators from physics, chemistry, pharmacy, mathematics, engineering, and medicine in an integrative perspective that goes "from molecules to man".

We are confident that the combination of high-level scientific lectures, back-to-basics educational sessions and fruitful discussions, together with nice social events will make the 21st edition of ESRR successful, continuing its long-standing tradition of excellence.

Antero Abrunhosa
Francisco Alves
Liliana Damas

TABLE OF CONTENT

ORGANISATION

Scientific Programme Committee:

Chair: Peter Laverman (The Netherlands)
Martin Behe (Switzerland)
Filippo Lodi (Italy)
Jessica Bridoux (Belgium)
Frederik Cleeren (Belgium)
Thomas Mindt (Austria)
Marianne Patt (Germany)

Local Organising Committee:

Antero Abrunhosa
Francisco Alves
Liliana Damas

Organising Secretariat:

AV ESRR
c/o EANM Executive Office
Schmalzhofgasse 26
1060 Vienna, AUSTRIA
+43 1 890 44 27
+43 1 890 44 27-9
esrr@esrr.info
http://www.esrr.info

Congress Venue:

Convento São Francisco
Avenida da Guarda Inglesa, n.º1A
3040-193 Santa Clara, Coimbra
geral@coimbraconvento.pt
https://coimbraconvento.pt/pt/

EXHIBITORS & SPONSORS

We would like to thank all exhibitors and sponsors of the ESRR 2024 for their support!

ABX	ABX advanced biochemical compounds GmbH
BIOEMTECH	BIOEMTECH
eichrom	Eichrom Technologies
ELYSIA RAYTEST	Elysia-Raytest
GE HealthCare	GE HealthCare
iba	IBA SA
IONETIX	Ionetix Alpha
iRE ELiT	IRE ELiT
isotopia	Isotopia Molecular Imaging Ltd.
itm	ITM Isotopen Technologien München AG
HUAYI TECHNOLOGY	Jiangsu Huayi Technology Co., Ltd.
LabLogic	LabLogic Systems Limited
	Molecubes
RCTEM	Rotem GmbH
Telix	Telix Pharmaceuticals
TRASIS	Trasis
TRISKEM	Triskem
VON GAHLEN	Von Gahlen

PROGRAMME OVERVIEW

Programme information based on March 27, 2024

Thursday, April 18, 2024

19:30	Welcome Ceremony & Welcome Lecture: AI in chemistry, with focus on data-driven reaction prediciton ***Teodoro Laino, Zurich***
20:30	Welcome Reception

Friday, April 19, 2024

08:30	Sci Session I – Imaging tracers Back-to-basics I: Novel agents and future prespectives on theranostics - ***Filipe Elvas, Antwerp***
10:05	Coffee Break
10:35	Session II – Auger and other therapeutic emitters Invited Lecture 1: Auger electron therapy - ***Samantha Terry, London***
12:20	Lunch
13:45	Session III – New oncological radiotracers Invited Lecture 2: Improving radioimmunotherapy with immuno/chemotherapy/ EBRT – a winning combination? - ***Sanne van Lith, Nijmegen***
15:30	Coffee Break
16:00	Session IV Debate: Small molecules vs peptides vs antibodies vs antibody fragments as vector molecule for theranostic radiopharmaceuticals - ***Frederik Cleeren, Leuven***
16:45	Poster Pitches (Sala Mondego)
16:45	Poster viewing + refreshments (Sala Aeminium)
20:00	Dinner (see page 13)

Saturday, April 20, 2024

08:30	Session V – Radiochemistry Back-to-basics II: Computational methods in radiopharmaceutical sciences - ***Verena Pichler, Vienna***
10:05	Coffee Break
10:35	Session VI – New neurological tracers Invited Lecture 4: Pretargeting strategies, where are we? - ***Mathias Herth, Copenhagen***
12:08	Workshop: EATRIS EU Tracer Factory - ***Nadja van Camp, The Netherlands*** ***Albert D. Windhorst, The Netherlands***
13:00	Lunch
14:00	Session VII – New infection and inflammation tracers Invited Lecture 5: Tracking cells with radiopharmaceuticals: strategies and applications - ***Aljaž Socan, Ljubljana***
15:30	Coffee Break
16:00	Session VIII – Round table GMP and Legislation (Annex 1 and 3) Regulators view on Annex 1 for radiopharmaceuticals - ***Thijs Kroon, Neil Hartman, Oliver Kiss***
17:30	Pharmacopoeia Corner - ***Thijs Kroon, Ellen Pel***
20:00	Dinner (see page 13)

Sunday, April 21, 2024

08:30	Session IX – From alpha to beta & back Back-to-basics III: Alpha emitters, from basic physics to labeling and measuring ***- Janke Kleynhans, Leuven***
10:05	Coffee Break
10:35	Session X – Radionuclide production Oral Presentations
11:25	Closing / Awards Ceremony
12:15	Farewell Lunch

SCIENTIFIC PROGRAMME

Friday, April 19, 2024

08:30 – 10:05	Session I – Imaging tracers **Chairpersons: Jessica Bridoux, Filipe Elvas**
08:30	***Filipe Elvas:*** Back-to-basics I: Novel agents and future prespectives on theranostics
09:15	***Alexandra Fonseca:*** OP01 Improved PET imaging of NETs with [61Cu]-NOTA-TATE: a straightforward comparison with [61Cu]-/[68Ga]-DOTA-TATE
09:27	***Anna Orlova:*** OP02 Development of SPECT agent [99mTc]Tc-BQ0413 for PSMA visualization: preclinical evaluation and preliminary results of Phase I clinical study
09:39	***Joana Santos:*** OP03 Folate-targeted polymeric micelles for image-guided drug delivery of an anticancer gold complex
09:51	***Emma Nascimbene:*** OP04 Development and characterization of 99mTc-scFvD2B as a potential theranostic pair for 177Lu-scFvD2B
10:05	Coffee Break
10:35 – 12:20	Session II – Auger and other therapeutic emitters **Chairpersons: Peter Laverman, Samantha Terry**
10:35	***Samantha Terry:*** Invited Lecture 1: Auger electron therapy
11:20	***António Paulo***: OP05 111In- and 161Tb-Radioconjugates Carrying PSMA and Triphenylphosphonium Derivatives for Auger Therapy of Prostate Cancer
11:32	***Marianna Tosato***: OP06 Sulfur Symphony: Capturing the Exotic Mercury-197m/g Auger Emitters with Macrocyclic S-Rich Chelators
11:44	***Thomas Mindt:*** OP07 Synthesis and preclinical evaluation of BOLD-100 radiolabeled with ruthenium-97/103
11:56	***Aleksander Bilewicz:*** OP08 Nanobioconjugates of 109Pd/109mAg in-vivo generators for targeted Auger electron therapy

12:08	***Laurène Wagner***: OP09 Synthesis, 68Ga-radiolabelling and in vitro evaluation of a PET/PDT agent for prostate cancer theranostics
12:20	Lunch
13:45 – 15:30	Session III – New oncological radiotracers **Chairpersons: Sanne van Lith, Inês Farinha Antunes**
13:45	***Sanne van Lith***: Invited Lecture 2: Improving radioimmunotherapy with immuno/chemotherapy/EBRT – a winning combination?
14:30	***Sarandeep Kaur***: OP10 Structure-based design, optimization and development of [18F]SK60: A Novel PET radioligand for the imaging of mutated Isocitrate Dehydrogenase
14:42	***Vladimir Tolmachev***: OP11 Molecular Imaging of HER2 Expression in Breast Cancer Using DARPin [123I]I-(HE)3-G3. From mice to Phase I.
14:54	***Herlinde Dierick***: OP12 Fully automated production of [18F]FB-labeled single-domain antibodies: the immune-checkpoint TIGIT for PET imaging
15:06	***Muriel Aline Spahn***: OP13 A novel Al18F-labeled radiotracer for in vivo imaging of CXCR4 using positron emission tomography
15:18	***Jonas Schädlich***: OP14 Radioiodinated closo-dicarbadodecaborane(12)-based cyclooxygenase-2/5-lipoxygenase inhibitors
15:30	Coffee Break
16:00 – 18:00	Session IV **Chairpersons: Martin Behe, Thomas Mindt**
16:00	***Frederik Cleeren:*** Debate: Small molecules vs peptides vs antibodies vs antibody fragments as vector molecule for theranostic radiopharmaceuticals
16:45	Poster Pitches (Sala Mondego)
17:15	Poster & Refreshments (Sala Aeminium)
20:00	Dinner (see page 13)

SCIENTIFIC PROGRAMME

Saturday, April 20, 2024

08:30 – 10:05	Session V – Radiochemistry **Chairpersons: Matthias Herth, Verena Pichler**
08:30	***Verena Pichler***: Back-to-basics II: Computational methods in radiopharmaceutical sciences
09:15	***Magdalena Blei***: OP15 Synthesis, stability determination and radiolabeling of new diazabenzene-based azamacrocycles with barium-131, actinium-225, lanthanum-133, and lead-212
09:27	***Ludovic Le Saux***: OP16 Evaluation of sydnones-based click chemistry for the labeling with heavy radiohalogens
09:39	***Eline Hooijman***: OP17 From Theory to Clinical Application: Understanding Ac-225 radiochemistry through [225Ac]Ac-DOTA-TATE
09:51	***Mátyás Fodor***: OP18 Radiolabelling of various macrocyclic ligands using 155Tb/156Tb radioisotopesn
10:05	Coffee Break
10:35 – 12:20	Session VI – New neurological tracers **Chairpersons: Philip Elsinga, Bieneke Janssen**
10:35	***Mathias Herth:*** Invited Lecture 4: Pretargeting strategies, where are we?
11:20	***Vanessa Tomé***: OP19 11C-carboxylations using Grignard reactions for the preparation of [carbonyl 11C]WAY-100635 and [1-11C]Sodium Acetate
11:32	***Romy Cools*** OP20 Preclinical evaluation of [11C]HSP990 as novel Hsp90 PET brain probe for in vivo visualization of Hsp90 in healthy aging and neurodegeneration
11:44	***Johanna Trommer***: OP21 Radiolabeling of M13 bacteriophages for in vivo imaging
11:56	***Albert D. Windhorst***: OP22 Synthesis, in vitro and in vivo evaluation of novel radioligands for α-synuclein PET
12:08	***Nadja van Camp, Albert D. Windhorst:*** Workshop: EATRIS EU Tracer Factory
13:00	Lunch

14:00 – 15:30	Session VII – New infection and inflammation tracers **Chairpersons: Aljaž Socan, Jan Rijn Zeevaart**
14:00	***Aljaž Socan***: Invited Lecture 5: Tracking cells with radiopharmaceuticals: strategies and applications
14:42	***Clemens Decristoforo***: OP23 Repurposing a pharmaceutical development for infection theranostics
14:54	***Gerbren B. Spoelstra***: OP24 Synthesis and preclinical evaluation of novel 18F-vancomycin-based tracers for the detection of bacterial infections using positron emission tomography
15:06	***Milos Petrik***: OP25 Artificial biomimetic Siderophores as PET radiopharmaceuticals: Radiolabelling and evaluation for PET imaging of invasive aspergillosis
15:18	***Julia Greiser***: OP26 [68Ga]Ga-TEoS-DAZA as PET tracer for liver function determination and diagnosis of liver-bile-related diseases
15:30	**Coffee Break**
16:00 – 18:00	Session VIII – Round table GMP and Legislation (Annex 1 and 3) **Chairpersons: Marianne Patt, Clemens Decristoforo**
16:00	Regulators view on Annex 1 for radiopharmaceuticals
16:30	***Thijs Kroon***: Problems arising from revised Annex 1 for preparation of radiopharmaceuticals
16:50	***Neil Hartman:*** Practical problems with Annex 1 for kit-based Radiopharmaceuticals and how a revision of Annex 3 help with the issues
17:05	***Oliver Kiss:*** Outcome from an ITF EMA meeting of PRISMAP (quality requirements for new radionuclides in clinical trials)
17:15	Discussion
17:30	***Thijs Kroon, Ellen Pel:*** Pharmacopoeia Corner
20:00	Dinner (see page 13)

SCIENTIFIC PROGRAMME

Sunday, April 21, 2024

08:30 – 10:05	Session IX – From alpha to beta and back **Chairpersons: Janke Kleynhans, Klaus Kopka**
08:30	***Janke Kleynhans:*** Back-to-basics III: Alpha emitters, from basic physics to labeling and measuring
09:15	***Cristina Müller:*** OP27 Tumor-targeted alpha therapy using terbium-149 in combination with somatostatin analogues
09:27	***Agnieszka Majkowska-Pilip:*** OP28 Synergistic effects of a combination of trastuzumab-emtansine (T-DM1) and β-radiation (198AuNPs) for targeted HER2+ therapy
09:39	***Laura De Nardo:*** OP29 Assessment of cell damage produced by somatostatin analog radiopharmaceuticals labelled with 177Lu or 161Tb
09:51	***Zbynek Novy***: OP30 Preclinical assessment of enhanced blood retention and tumor uptake PSMA-targeting 225Ac-labeled radioconjugates
10:03	Coffee Break
11:15 – 11:25	Session X – Radionuclide production **Chairpersons: Nicholas van der Meulen, Tom Christian Adamsen**
10:35	***Nicholas van der Meulen***: IOP31 Terbium-149 production and separation: the latest development update
10:47	***Francesca Barbaro***: OP32 155Gd-target enrichment for 155Tb production by low-energy cyclotrons
10:59	***Giorgia Speltri:*** OP33 Development of a new technology for the 52Mn-radiopharmaceuticals cyclotron production
11:11	***Santiago Brühlmann***: OP34 An alternative production route for the PET radionuclide 61Cu: exploring the 62Ni(p,2n)61Cu nuclear reaction
11:25	Closing / Awards Ceremony
12:15	Farewell Lunch

SOCIAL PROGRAMME

Thursday, April 18, 2024

20:30
Welcome Reception
(Congress Venue)

Friday, April 19, 2024

19:00
Quinta das Lágrimas,
Rua António Augusto Gonçalves
Coimbra, 3041-901

Saturday, April 20, 2024

20:00
Sala D. Afonso Henriques
(church at congress venue)
Meeting point in front of the church

Sunday, April 21, 2024

12:15
Farewell Lunch
(Congress Venue)

POSTER PRESENTATIONS

PP01
Addressing the side product challenge in copper-mediated radiofluorination
Sarandeep Kaur, Germany

PP02
The importance of radiochemical purity: Cellular binding and internalization of different radiometal chlorides in prostate cancer cells
Julia Raitanen, Austria

PP03
TECANT Journey: Tracing the Path of 99mTc-labelled Somatostatin Antagonist from Concept to Clinical Realization
Renata Mikolajczak, Poland

PP04
The potential use of palladium radionuclides for Targeted Auger electron Therapy (103Pd) and theragnostic applications (109Pd)
Cathryn HS Driver, South Africa

PP05
Fully automated, GMP-compliant, one-pot production of 6-L-[18F]FDOPA using an optimized [18F]fluorodestannylation Approach
Chantal Kwizera, The Netherlands

PP06
Advancing into the realm of innovative theranostic radionuclides: separation of silver-111 from a neutron-irradiated palladium target
Mattia Asti, Italy

PP07
Modelling ligand depletion for simultaneous affinity and binding site quantification on cells and tissue
Hadis Westin, Sweden

PP08
Cationic amino acid-based technetium(I)-99m complexes for cancer imaging
Rúben Silva, Portugal

PP09
Fast Screening tools: Unveiling molecular insights through nuclear in vivo imaging and efficient preclinical research
Sofia Lagoumtzi, Greece

PP10
Preclinical imaging of therapeutic alpha-emitters
Sofia Lagoumtzi, Greece

PP11
Microwave in PET Radiochemistry
Ângela Neves, Portugal

PP12
Novel concept of a 44Ti/ 44Sc generator
Đorđe Cvjetinović, Switzerland

PP13
Automation of 11C-labelled TSPO-tracer [11C]Me-DPA synthesis with Trasis AllInOne-module
Edla Kerminen, Finland

PP14
Cytotoxic and Antiproliferative Effects of [64Cu]CuCl2 in Tumor Cells for Radiometabolic Therapy: a Preliminary Study
Francesca Porto, Italy

PP15
PSMA-radioligand therapy: Institutional Experience
Mohammed Al-Qahtani, Saudi Arabia

PP16
Radiolabelling of [68Ga]Ga-NODAGA-Exendin-4 in sodium acetate buffer
Maïlys Ragot, France

PP17
Clearing Agents based on Poly-L-Lysine scaffolds for improved Pretargeted α-Radioimmunotherapy
Emma Aneheim, Sweden

PP18
Radiolabelled antiangiogenic monoclonal antibody ramucirumab as an effective tool for diagnostics and therapy in nuclear medicine
Pavel Barta, Czech Republic

PP19
Preparation and evaluation of stabilized 211At-labelled aryl compounds
Romain Fouinneteau, France

PP20
Synthesis and characterization of Rhenium and Technetium-99m nitrido complexes with tridentate thiosemicarbazones ligands
Cristina Bolzati, Italy

PP21
67Cu produced at a biomedical cyclotron for preclinical in vivo studies
Ursula Søndergaard, Norway

PP22
Production of research radionuclides for Targeted Auger Electron Therapy (TAET) at TRIUMF
Valery Radchenko, Canada

PP23
The development of lyophilised kit preparations: Gateway to larger clinical uptake of Ga-68 radiopharmaceuticals
Jan Rijn Zeevaart, South Africa

POSTER PRESENTATIONS

PP24
Challenges in IMP preparation for a clinical trial – on the example of DuoNen, personalized PRRT with mixed doses of [177Lu]Lu-DOTA-TATE and [90Y]Y-DOTA-TATE in neuroendocrine neoplasm treatment
Renata Mikolajczak, Poland

PP25
3D cancer models for the theranostic evaluation of 64CuCl2
Filipa Mendes, Portugal

PP26
The Potential of Terbium-161 labeled Compounds for Clinical Implementation
Carolline Ntihabose, The Netherlands

PP27
Implementing Ac-225 Labelled Radiopharmaceuticals: Practical Considerations and (Pre-)Clinical Perspectives
Eline Hooijman, The Netherlands

PP28
Development and primary evaluation of [99mTc]Tc (CO)3-NOTA-Erlotinib as a potential radiopharmaceutical for molecular imaging in triple negative breast cancer
Ana María Rey, Uruguay

PP29
A novel capsule design results in efficient production of 89Zr
Johan Svedjehed, Sweden

PP30
A novel dual-modality imaging agents targeting FAP based on fusarinine C scaffold
Giacomo Gariglio, Austria

PP31
Optimization and Automation of Copper-mediated one-step [18F]SFB synthesis starting from the boronic acid pinacol ester
Markus Laube, Germany

PP32
Implementation of Design of Experiments methodology for optimization of 18F-PSMA-11 radiolabeling with {Al18F}2+ on AIO
Charlotte Collet-Defossez, France

PP33
Fully-automated production of [18F]Amylovis on the trasis AllinOne module
Fernando Trejo-Ballado, Mexico

PP34
89Zr-DFO-Atezolizumab for PD-L1 Imaging of Glioblastoma: Clinical Experience
Anna Kastelik-Hryniewiecka, Poland

PP35
Investigation into the metabolic stability of 18F-labeled PSMA inhibitor derivatives bearing aryl-fluorosulfates for PET tracer development applications
Guillermo Luque Consuegra, Germany

PP36
Biodistribution of orally administered nano-particle polymers
Steen Jakobsen, Denmark

PP37
Titanium-45 – Production, Extraction and Complexation
Chubina Kumarananthan, Norway

PP38
Synthesis and Quality Control of [68Ga]Ga-PSMA-11 Cold Kits Produced Using Two Different Generator Models Simultaneously
Daniele Alizé, France

PP39
Improvement of the local macroaggregated albumin (MAA) lyophilised kit
Putthiporn Charoenphun, Thailand

PP40
A fast and automated method for the production of [13N]AMMO
Ole Heine Kvernenes, Norway

PP41
Exploring the therapeutic efficacy of [177Lu]Lu-DOTA-trastuzumab in trastuzumab-resistant HER2+ lesions
Liliana Santos, Portugal

PP42
Sequential labeling of Silk Fibroin Nanoparticles with 99mTc and Indocyanine Green for in vivo SPECT NIR-I/II imaging: Towards photothermal theranostic nanoprobes
Belén Otero Alonso, Spain
Andrea Blesa Jiménez, Spain

PP43
211At-labeling of trans-cyclooctenes and cis-cyclooctenes with astatine-211 using electrophilic and nucleophilic reactions
Maarten Vanermen, Belgium

PP44
The role of radiopharmaceutical Tc99m MIBI in the evaluation of parathyroid adenoma and osteoporosis in young patients - a case report supporting its integration into standard clinical practice
Ismet Bajrami, Kosovo

PP45
In-hospital production and quality control of radiotracer [68Ga]Ga-NODAGA-Exendin-4 on Trasis EasyOne synthesizer
Sonja Van den Block, Belgium

PP46
Manufacturing of investigational medicinal products under GMP conditions using the example of a radiopharmaceutical kit PSMA-T4 for technetium-99m labelling
Anna Drapsa, Poland

POSTER PRESENTATIONS

PP47
Radionuclidic purity of Ga-68 eluted from Ge-68/Ga-68 generators by Thin Layer Chromatography
Joao Alberto Osso Junior, Brazil

PP48
[225Ac]Ac-PSMA-D4 as a promising alpha-emitter based radiopharmaceutical Preliminary studies - radiolabelling and quality control
Marcin Radzik, Poland

PP49
[18F]Fluoromisonidazole synthesis method based on solid-phase extraction (SPE) purification
Maja Chochevska, North Macedonia

PP50
Pharmacoeconomic analysis as a tool for more objective insight into the idea of introducing new radiopharmaceuticals
Katerina Kolevska, North Macedonia

PP51
Application of autoradiography to study radionuclide distribution in 3D culture models
Catarina Pinto, Portugal

PP52
Validation of an in-house process for the production of Sodium [18F]fluoride radiopharmaceutical
Marija Atanasova Lazareva, North Macedonia

PP53
Preliminary evaluation of a novel Temozolomide-based molecule radiolabeled with 99mTc as a theranostic agent against glioblastoma
Penelope Bouziotis, Greece

PP54
PSMA-targeted Radioconjugates Bearing a DNA Intercalator for Enhanced Auger Therapy of Prostate cancer
Catarina Dorisa Silva, Portugal

PP55
Therapeutic Efficacy of 177Lu-DMSA-SPIONs in a Mouse CT26 and 4T1 Xenograft Model
Dragana Stanković, Serbia

PP56
NOAR - Network for Optimized Astatine-211 labeled Radiopharmaceuticals EU COST Action CA19114
Dana Niculae, Romania

PP57
Automated production of [68Ga]Ga-deferoxamine on two different synthesis modules for bacterial infection imaging
Martin Kraihammer, Austria

PP58
First automatic multidose injection of the 177Lu-ITG-PSMA-1 in Bosnia and Herzegovina
Aljoša Stanković, Bosnia & Herzegovina

PP59
Unlocking the potential of 45Ti for PET-imaging: the formation and evaluation of the Ti-DOTA complex
Eduard Pogorilyy, Norway

PP60
Automated fluorine-18 radiolabelling via alkyne-azide cycloaddition reaction on dual peptide-functionalized liposomes surface for in vivo PET imaging
Marco Nicola Iannone, Italy

PP61
Development of [18F]AlF-RESCA-FSH as a diagnostic probe for ovarian cancer.
Maria Kominia, The Netherlands

PP62
Design and evaluation of Cu(II)-HMPAO complex as a representative model for assessing the potential of 64Cu radiopharmaceutical
Marija Mirković, Serbia

PP63
Using Epin boronic esters as substrates improves the copper-mediated [18F]-fluorination of arenes
Annemarie Doze, The Netherlands

PP64
Effects of the conjugation method on the stability of a 161Tb-labeled antibody
Camille Van Laere, Belgium

PP65
Liquid target production of zirconium-89 for antibody labelling
Agnieszka Chmura, Poland

PP66
Copper-61: From Bench to Bedside
Nicole Schubert, Germany

EXHIBITION PLAN

Venue Overview

The scientific programme will be held in **Sala Mondego** which is located on the second floor.
The industry exhibition will be set up in **Sala Aeminium** which is on the first floor.

Main Entrance

Convento São Francisco
Avenida da Guarda Inglesa, n.º1A
3040-193 Santa Clara, Coimbra

Industry Exhibition

Floor 1 - Sala Aeminium

Scientific Programme

Floor 2 - Sala Mondego





Booth	Company
01	IRE ELiT
02	Von Gahlen
03	Elysia-Raytest
04	Rotem GmbH
05	Telix Pharmaceuticals
06	Ionetix Alpha
07	Molecubes
08	ABX advanced biochemical compounds GmbH
09	Triskem
10	LabLogic Systems Limited
11	IBA SA
12	Eichrom Technologies
13	Isotopia Molecular Imaging Ltd.
14	Trasis
15	Jiangsu Huayi Technology Co., Ltd.
16	BIOEMTECH
17	ITM Isotopen Technologien München AG
18	GE HealthCare

TRISKEM
Expertise in Separation Chemistry

Radiopharmacy

Environment

Geochemistry

Decommissioning

Highly selective resins for radiometal purification

Separation methods for Ga-68, Cu-61/4/7, radiolanthanides (Lu-177, Tb-161,...), Zr-89, Ge-68, alpha emitters (Ac-225, Pb-212,...), Ti-44/5 and many more.

Rapid, highly specific separation techniques
Separation of radionuclides from irradiated targets
Quality control of radionuclides for medical use
R&D and method development
Radioprotection and Radioanalysis

Meet us at our booth n° 9

To keep up to date with our new developments subscribe to our newsletter.

www.triskem.com

Notes

Notes

Notes

HUAYI TECHNOLOGY

CMO Services for Radiopharmaceuticals

APIs

We have the flexibility to run multiple chemical processes simultaneously to support late development phase to commercial products. State-of-the-art QC laboratories integrated across a highly experienced team focused on commercial readiness and manufacturing expertise.

Full support for method development, validation, and transfer services, as well as submission, audit and manufacturing support.
- PSMA 11
- chrial-PSMA I&T

Scan for more compounds

Cassettes

With years of experience, we offer GMP-compliant cassette production services for your new radiolabeled compounds, supporting your innovative radiopharmaceutical development.



Ready-to-use kits for ^{18}F-FDOPA production

IBA Synthera+ synthesis module

Scan for more RTU kits

Reagents Kit | RK-209

Precursor | BBTE-95-0020E

Ancillaries Set | AS-209

Cassette | SYFR

International
☎ +1 416 298 3366
✉ Antony@huayi-isotopes.com

China
☎ +86 512 52451806
✉ sales@huayitec.net

www.huayitec.net
Follow us: